Related Experiment Video
Updated: Nov 3, 2025
Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
Published on: June 27, 2025
Prognostic and immunomodulatory effects of PIM1 in colorectal carcinoma
Yun Zhou1, Yongning Zhou, Shixiong Liu
1Department of Geriatrics (II), The First Hospital of Lanzhou University, Lanzhou 730000, P.R. China.
Purpose:
Proviral integration of Moloney murine leukemia virus (PIM) family kinases can promote the survival and movement of carcinoma cells and the metastatic growth of various types of carcinoma. However, there are few studies on PIM1 in colorectal carcinoma (CRC), so we decided to investigate this issue.
Methods:
Data about PIM1 expression and clinical and mutation information were downloaded from The Carcinoma Genome Atlas (TCGA). Survival analysis was performed by Kaplan-Meier method and the cumulative incidence of survival events was calculated. The correlation of PIM1 mRNA expression and immune infiltration score with the mutation index (TMB; tumor mutational burden), MSI (microsatellite instability)) was tested by Spearman's method. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of PIM1 enrichment and carcinoma-related pathways in CRC were performed.
Results:
PIM1 was elevated in most carcinomas, especially CRC. In CRC, PIPM1 had a correlation with the overall survival (OS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI). They indicated that PIPM1 acts in the progression of CRC. PIM1 was correlated with MSI, immune score and immune cell infiltration. Thereby it linked its expression with the evaluation of treatment response.
Conclusions:
Bioinformatics analysis confirmed PIM1 as a good biomarker for the prognosis and treatment evaluation of CRC.
